National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.
Explore this paper's citation graph
Summary
These revisions evolved as the guidelines were used in a systematic fashion in large clinical trials and with the experience following the use of newer, more effective agents, such as fludarabine.
- Type
- article
- Published
- 1996-06-15
- Cited by
- 1,974
- References
- 36
- Access
- Open access
- OpenAlex
- https://openalex.org/W60865865
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:14630626
Keywords
Medicine, Chronic lymphocytic leukemia, Fludarabine, Internal medicine, Clinical trial
References
- bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia.
- p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.
- Clinical staging of chronic lymphocytic leukemia.
- High frequency of monoallelic retinoblastoma gene deletion in B-cell chronic lymphoid leukemia shown by interphase cytogenetics.
- Bone marrow histologic pattern--the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases.
- Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.
- Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.
- Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.
- Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia.
- A clinical staging system for chronic lymphocytic leukemia. Prognostic significance
- Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
- HLA-Identical Sibling Bone Marrow Transplantation in Younger Patients with Chronic Lymphocytic Leukemia
- Evidence for a new tumour suppressor locus (DBM) in human B–cell neoplasia telomeric to the retinoblastoma gene
- A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
- Treatment of early chronic lymphocytic leukemia: Intermittent chlorambucil versus observation
- Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results.
- True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases.
- Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia.
- High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count.
- Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis.
Cited by
- Proteomic characterisation of chronic lymphocytic leukaemia cells treated with rituximab
- In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues – correlation with clinical course
- Is there still a place for clinical staging in chronic lymphocytic leukaemia?
- Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia.
- Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia
- Immunotherapy of chronic lymphocytic leukemia
- Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
- Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B‐cell chronic lymphocytic leukaemia
- Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology Group.
- Changing the way we think about chronic lymphocytic leukemia.
- Inefficiency of high-dose G-CSF alone as second mobilization regimen in fludarabin-cyclophosphamide-treated CLL patients who failed to mobilize after chemotherapy and G-CSF
- The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience
- Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
- IGHV gene insertions and deletions in chronic lymphocytic leukemia: “CLL‐biased” deletions in a subset of cases with stereotyped receptors
- Use of optophoresis as an in vitro predictor of cell response to chemotherapy for chronic lymphocytic leukemia
- CXC Chemokine Ligand 13 and CC Chemokine Ligand 19 Cooperatively Render Resistance to Apoptosis in B Cell Lineage Acute and Chronic Lymphocytic Leukemia CD23+CD5+ B Cells1
- Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14.
- Stem cell transplantation in poor‐risk chronic lymphocytic leukemia: assessment of post‐transplant minimal residual disease using four‐ and six‐color flow cytometry and allele‐specific RQ‐PCR
- B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome.
- Rituximab based therapy followed by autologous stem cell transplantation leads to superior outcome and high rates of PCR negativity in patients with indolent B-cell lymphoproliferative disorders
Related papers
- 5.27 Low-Dose Fludarabine and Cyclophosphamide Combined With Rituximab Is a Safe and Effective Treatment Option for Elderly and Comorbid Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Preliminary Results of Project Q-lite, by the Czech CLL Study Group
- Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine.
- Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia
- Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials
- Recurrence of autoimmune thrombocytopenia after treatment with fludarabine in a patient with chronic lymphocytic leukemia.
- Fludarabine a major new drug in chronic lymphocytic leukemia (CLL)
- IX. Chronic lymphocytic leukemia for the clinician
- [Successful combined treatment with rituximab and high dose immunoglobulin in a patient with chronic lymphocytic leukemia with fludarabine-induced severe immune thrombocytopenia].